Potassium

證據等級: L5

預測適應症: 5 個

Potassium: From Electrolyte Supplementation to Hypertensive Disorder

One-Sentence Summary

Potassium (DB14500) is an essential mineral clinically recognized for correcting hypokalemia and sustaining normal cellular, cardiac, and vascular function. The TxGNN model predicts it may be therapeutically relevant for Hypertensive Disorder, a prediction backed by a landmark NEJM outcomes RCT, multiple Tier-1 meta-analyses, and a well-characterized molecular mechanism spanning basic science through large-scale clinical evidence. Evidence is classified as L1 — the highest level in this framework — making this the most strongly supported prediction in the current candidate set.

Quick Overview

Item	Content
Original Indication	Electrolyte supplementation; correction of hypokalemia
Predicted New Indication	Hypertensive Disorder
TxGNN Prediction Score	99.16%
Evidence Level	L1
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Potassium is not merely a passive electrolyte — it is an active regulator of blood pressure through at least four distinct, well-documented pathways. First, dietary potassium activates the Ppp1Ca–Ppp1r1a dephosphorylation axis in renal distal tubule cells, suppressing the sodium-chloride cotransporter (NCC) and directly promoting urinary sodium excretion — a mechanism recently confirmed at the molecular level in a Journal of Clinical Investigation study (Grimm et al., 2023). Second, adequate potassium status suppresses renin secretion, downregulating the renin-angiotensin-aldosterone system (RAAS) axis. Third, elevated extracellular potassium concentrations hyperpolarize vascular smooth muscle cell membranes, inducing arterial vasodilation. Fourth, high potassium intake directly blunts the pressor response to dietary sodium excess — the so-called sodium–potassium antagonism that underpins the benefit of potassium-enriched salt substitutes.

This mechanistic profile parallels two of the most established antihypertensive drug classes: thiazide diuretics (which promote natriuresis) and RAAS inhibitors (which preserve potassium). It is therefore not surprising that conditions marked by potassium wasting — such as primary aldosteronism and renovascular hypertension — are precisely those associated with the most severe and treatment-resistant hypertension. Correcting potassium deficiency in these settings is not merely supportive care; it disrupts the upstream hormonal cascade driving blood pressure elevation.

The clinical evidence has matured well beyond hypothesis. The SSaSS trial (Neal et al., NEJM 2021), conducted in nearly 21,000 high-risk participants, demonstrated that a potassium-enriched salt substitute reduced stroke by 14%, major cardiovascular events by 13%, and cardiovascular death by 12%. Multiple independent systematic reviews and dose-response meta-analyses confirm a linear, significant blood pressure–lowering effect of potassium supplementation, particularly in hypertensive individuals. TxGNN’s L1-level prediction is therefore not a novel speculation but a computational confirmation of a well-established biological relationship.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01429246	N/A	Completed	282	Single-blind RCT in Tibet (4,300 m altitude): KCl-based salt substitute vs. standard salt in known hypertensives (SBP ≥140 mmHg); primary endpoint was blood pressure reduction — the most directly relevant trial for potassium supplementation in hypertension
NCT00079690	N/A	Completed	~1,200	Genetic epidemiology of BP intervention: identifies gene variants modulating BP response to low/high dietary sodium, oral potassium supplementation, and cold pressor — includes a dedicated potassium supplementation arm
NCT07137364	N/A	Recruiting	350	Observational study of spironolactone dosing in lateralized primary aldosteronism (PA); potassium correction and homeostasis are central to BP management in PA, providing indirect evidence for potassium’s role in secondary hypertension
NCT05814770	Phase 4	Not Yet Recruiting	96	RCT: finerenone vs. spironolactone in primary aldosteronism; serum potassium is a primary safety and efficacy endpoint, directly evaluating potassium homeostasis in mineralocorticoid-excess hypertension
NCT00887250	Phase 3	Completed	366	Double-blind RCT: losartan 50–100 mg vs. placebo in mild-to-moderate essential hypertension; losartan’s potassium-sparing property (via RAAS inhibition) is one of the proposed mechanisms of BP reduction
NCT00496834	Phase 4	Completed	201	Losartan potassium vs. carvedilol in essential hypertension — arterial stiffness (PWV) as primary endpoint; evaluates downstream cardiovascular consequences of potassium-preserving antihypertensive therapy
NCT02832973	Phase 4	Completed	72	ResHypOT: sequential nephron blockade (includes potassium-sparing aldosterone antagonism) vs. dual RAAS blockade + bisoprolol in resistant hypertension; serum potassium monitoring integral to both arms
NCT02059811	N/A	Completed	42	Pilot RCT of DASH diet (a potassium-rich dietary pattern) for uncontrolled hypertension in CKD; evaluates BP lowering from dietary potassium increase in a renally impaired population
NCT03640312	Phase 2	Completed	62	QUARTET USA: ultra-low-dose quadruple combination therapy vs. standard monotherapy in hypertension — includes potassium-sparing agents; relevant to combination strategies using potassium-preserving drugs
NCT04026776	Early Phase 1	Recruiting	120	Investigates how dietary Na/K ratio influences blood pressure and salt sensitivity in young adults born preterm — directly examines potassium–sodium interplay in BP regulation

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34459569	2021	Large RCT (outcomes)	N Engl J Med	SSaSS trial (n≈20,995): potassium-enriched salt substitute reduced stroke by 14%, major CV events by 13%, and CV death by 12% in high-risk hypertensive adults; landmark evidence for real-world potassium benefit
32500831	2020	Systematic Review & Meta-Analysis of RCTs	J Am Heart Assoc	Dose-response meta-analysis of RCTs (≥4 weeks): potassium supplementation produces a significant, linear reduction in both systolic and diastolic BP; effect strongest in hypertensive individuals
23558164	2013	Systematic Review & Meta-Analysis	BMJ	WHO-commissioned analysis: increased potassium intake reduces BP and stroke risk by 24%; no adverse effects on blood lipids, kidney function, or renal hormones in healthy adults
37772757	2024	State-of-the-Art Review	Am J Hypertens	Comprehensive update on potassium mechanisms in hypertension: NCC suppression, RAAS modulation, and vascular hyperpolarization reviewed; authors argue potassium deserves a dedicated place in hypertension guidelines
39472546	2025	Expert Review	Hypertens Res	Asia-Pacific consensus on dietary potassium and salt substitution for hypertension: recommends potassium-enriched salt substitutes as a scalable, low-cost non-pharmacological intervention, particularly for Asian populations
37676724	2023	Mechanistic Study (Basic Science)	J Clin Invest	Identifies the Ppp1Ca–Ppp1r1a → NCC dephosphorylation pathway as the key mechanism by which dietary potassium induces natriuresis and BP reduction; transcriptomic validation in rodent models
30190007	2018	Clinical Guideline / Expert Review	J Am Coll Cardiol	JACC Health Promotion Series: identifies inadequate dietary potassium as a modifiable determinant of hypertension; endorses potassium supplementation alongside sodium restriction for BP management
27455317	2016	Narrative Review	Nutrients	Reviews potassium bioavailability, Na⁺/K⁺-ATPase physiology, and clinical evidence for BP reduction; discusses dietary sources, supplement forms, and bioequivalence considerations
29771736	2018	Evidence Synthesis Review	Curr Opin Cardiol	DASH diet and potassium-rich dietary patterns consistently lower BP in pre-hypertensive and hypertensive adults; highlights synergy between sodium reduction and potassium increase
23674806	2013	Comprehensive Review	Adv Nutr	Potassium classified as a “shortfall nutrient” by US Dietary Guidelines; moderate-to-strong evidence for BP reduction and stroke risk reduction; additional benefits for bone health and kidney stone prevention

Philippines Market Information

Potassium (DB14500) currently has no registered pharmaceutical products in the Philippines under this DrugBank entry. No FDA Philippines license records were retrieved.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	No registered products	—	No data available

While potassium-containing preparations (e.g., potassium chloride oral supplements, IV electrolyte solutions) are routinely stocked in Philippine hospitals as essential medicines, no formal registration linked to DrugBank ID DB14500 was found in the current dataset. A regulatory pathway review under FDA Philippines will be required to determine whether potassium supplementation products for hypertension require new drug registration or qualify as nutritional supplements.

Safety Considerations

Please refer to the package insert for safety information.

Important clinical context: Although formal safety data was not retrieved in this evidence pack, potassium supplementation carries well-recognized risks that are particularly relevant to the hypertensive population: hyperkalemia is a serious concern in patients with chronic kidney disease (CKD Stage ≥3), those on RAAS inhibitors, potassium-sparing diuretics, or NSAIDs — populations that overlap substantially with the hypertension target group. Risk stratification for renal function and concomitant medications should be a prerequisite for any formal repurposing program.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence that potassium supplementation lowers blood pressure in hypertensive adults is one of the most thoroughly established relationships in nutritional cardiology, supported by a NEJM outcomes RCT, multiple Tier-1 systematic meta-analyses, and a well-characterized molecular mechanism extending from the renal tubule to the vascular wall. TxGNN’s L1 classification is a validation of existing science rather than a novel hypothesis. The primary barriers to formal repurposing in the Philippines context are regulatory classification, safe patient selection, and formulation strategy — not evidence of efficacy.

To proceed, the following is needed:

Regulatory classification review: Determine whether potassium supplementation products (KCl oral tablets, salt substitutes) require new FDA Philippines pharmaceutical registration or may be advanced through a nutritional/functional food pathway
Renal safety protocol: Mandatory screening of eGFR and concurrent medication review (RAAS inhibitors, potassium-sparing diuretics, NSAIDs) before initiating supplementation; define contraindication cutoffs for CKD staging
Target population definition: Clarify eligibility criteria — potassium benefit is most pronounced in hypertensive individuals with documented low dietary potassium intake or mild hypokalemia, rather than all hypertensives
Formulation and dose selection: Determine optimal delivery vehicle (potassium chloride capsules vs. salt substitute program vs. dietary counseling) and target daily intake aligned with WHO/ACC guidance (3,500–4,700 mg/day)
Local dietary baseline data: Assess current potassium intake in hypertensive Filipino adults to project the expected magnitude of BP reduction and guide intervention intensity
Pharmacovigilance plan: Establish serum potassium and renal function monitoring intervals, particularly for higher-risk subgroups including the elderly and those with comorbid CKD or diabetes
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.